Raising $88.8M for Pivotal Study of Duravr TAVR Device
Heart valve developer Anteris Technologies made its debut on the U.S. stock market, raising $88.8 million through its IPO. Listed under the ticker symbol “AVR” on Nasdaq, the company plans to use proceeds to advance its Duravr transcatheter heart valve for treating severe aortic stenosis.
Key Highlights of the IPO
- Offering Details:
- Priced at $6 per share, with shares closing at $5.78 after Thursday’s trading session.
- Funds allocated for pivotal study enrollment, general corporate purposes, and debt repayment.
- Duravr Technology:
- A single-piece molded, bioengineered tissue valve, designed to mimic a healthy human valve.
- Uses Adapt tissue, FDA-cleared and clinically utilized for over a decade.
Positioning in the TAVR Market
Anteris aims to compete with industry giants Edwards Lifesciences and Medtronic, which dominate the transcatheter aortic valve replacement (TAVR) space. The company believes its innovative design could offer improved patient outcomes and efficiency.
A MedTech IPO Revival?
Medtech IPOs have been sparse, but analysts predict a market rebound in 2025 as economic conditions stabilize. Companies like Anteris could pave the way for renewed investor interest in medtech innovation.
Follow MEDWIRE.AI for insights into IPO activity and advancements shaping the future of healthcare technology.
